



(43) International Publication Date
26 September 2013 (26.09.2013)

(51) International Patent Classification:

A61K 47/48 (2006.01) A61K 38/34 (2006.01)
C07K 5/09 (2006.01)

(21) International Application Number:

PCT/US2013/029696

(22) International Filing Date:

7 March 2013 (07.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/613,212 20 March 2012 (20.03.2012) US

(71) Applicant: **HELIX BIOMEDIX INC** [US/US]; 22121
17th Avenue SE #112, Bothell, WA 98021 (US).

(72) Inventors: **ZHANG, Lijuan**; 20429 60th Ave. NE, Ken-
more, WA 98028 (US). **CARMICHAEL, Robin**; 4129
238th PL SE #54C, Bothell, Washington 98021 (US).

(74) Agents: **KAMMERER, Patricia, A.** et al.; Novak Druce
Connolly Bove + Quigg LLP, 1000 Louisiana, Fifty-third
Floor, Houston, TX 77002 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: SHORT ANTIMICROBIAL LIPOPEPTIDES

(57) Abstract: Disclosed are peptides having biological and therapeutic activity. Particularly disclosed are lipidated di- or tri- pep-
tides analogs of KPV or KdPT that exhibit antimicrobial activity. In particular, the peptides of this invention provide enhanced anti-
microbial activity over the base tri -peptides, lysine -proline- valine and lysine-d-proline-tyrosine. The disclosed peptides have the
general formula of C12-18 lipid— KXZ-NH₂i wherein K is lysine; X is proline, d-proline, histidine or arginine; Z is optional and if
present Z is valine, threonine, alanine or leucine; and the terminal COOH is NH₂ amidated. The C12-18 lipid is preferably the lipid
moiety of lauric acid (C12), myristic acid (C14), pentadecanoic acid (C15), palmitic acid (C16), or stearic acid (C18). The invention
is further related to methods of using of these peptides to treat various insults, inflammations or bacterial infections affecting the skin
and other related mucosal body surfaces such as the oral cavity.

